Insulin/Lixisenatide Combo Outperforms Insulin Mix Based on Beta-Cell Function Level | Research

The takeaway

iGlarLixi (insulin glargine + lixisenatide) showed differential efficacy versus IDegAsp based on baseline β-cell function, with greater benefits in patients with more preserved insulin secretion.

Beta-cell dependent
GLP-1-containing insulin combination works best when patients still have functioning insulin-producing cells

What the researchers found

iGlarLixi showed differential efficacy vs IDegAsp based on baseline β-cell function, with greater benefits in patients with more preserved insulin secretion capacity.

Why it matters

Knowing that GLP-1 combination drugs work best in patients with residual beta-cell function guides personalized treatment selection.

How the study worked

Exploratory analyses of the 24-week Soli-D RCT stratifying iGlarLixi vs IDegAsp outcomes by baseline β-cell function markers.

What this study cannot tell us

Exploratory analyses from a single trial. β-cell function measurement has limitations. Results may not generalize to all GLP-1-insulin combinations.

How to read the evidence

Exploratory analysis from a well-designed RCT. Important for personalization but needs prospective validation.

When this study was published

Published in 2025.

The bigger picture

This supports precision diabetes therapy: matching drug mechanisms to individual patient biology for optimal outcomes.

Questions still open

Should β-cell function testing guide GLP-1 drug prescribing?
At what level of β-cell function do GLP-1 drugs stop being beneficial?
Would tirzepatide show the same β-cell function dependency?

Common questions

What is iGlarLixi?

It is a once-daily injection combining insulin glargine (long-acting insulin) with lixisenatide (a GLP-1 drug). It provides insulin coverage plus GLP-1 benefits in a single shot.

Who benefits most from adding GLP-1 to insulin?

Patients whose pancreas still produces some insulin naturally. The GLP-1 component helps these remaining cells work better, providing greater benefit than in patients whose cells have completely failed.

Read the original research

Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.

Diabetes, obesity & metabolism, 28(1), 242-255

View on PubMed ↗Publisher’s paper ↗

Citation

Gu, Weijun; Wu, Xiaohong; Zhang, Minlu; Wang, Xinyi; Du, Qin; Kang, Lei; Lauand, Felipe; Alvarez, Agustina; Mu, Yiming. (2026). Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.. Diabetes, obesity & metabolism, 28(1), 242-255. https://doi.org/10.1111/dom.70181